Kuzu, BurakErguc, AliKarakus, FuatArzuk, Ege2025-05-102025-05-1020231054-25231554-812010.1007/s00044-023-03090-22-s2.0-85161401026https://doi.org/10.1007/s00044-023-03090-2https://hdl.handle.net/20.500.14720/10414Erguc, Ali/0000-0002-9791-4399; Kuzu, Burak/0000-0002-7305-7177; Karakus, Fuat/0000-0002-5260-3650In this study, a series of derivatives of thiazolyl-pyrazole hybrid structures were designed to search for new heterocyclic compound-based antitumor agents. The designed target structures were synthesized with easy, practical, and efficient procedures. The antiproliferative effect of the synthesized compounds against cancer cell lines A549, MCF-7, and HepG2 was evaluated regarding inhibition concentration and selectivity index against healthy cell line CCD-34Lu. The results overall showed that the compounds had high antiproliferation against cancer cells compared to the doxorubicin-positive control. In particular, compound 11 A549 (SI: 3.58) and HepG2 (SI: 12.36) had high selectivity in cancer cell lines, while compounds 10h and 10o had high selectivity (SI: 10.74 for both) in MCF-7 cancer cell lines. The calculated theoretical pharmacokinetic properties revealed that they could be suitable drug candidates. In addition, in vitro test results indicate a correlation between the structure-activity relationships of the compounds. The various molecular modifications of thiazolyl-pyrazole hybrid compounds are promising for developing new anticancer drug candidates.eninfo:eu-repo/semantics/closedAccessThiazolyl-PyrazoleAntiproliferationAdmetSarArticle328Q3Q216901700WOS:001004467600003